CHC – The Cancer & Hematology Centers

(SL03-OHD-105) Shattuck

Description: An Open-Label, Phase 1B Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Pegylated Liposomal Doxorubicin or Paclitaxel to Subjects with Platinum-Resistant Gynecological Cancers


Target Patient Population:  High grade ovarian, primary peritoneal or fallopian tube cancers.

Study Design:  Drug is given IV Day 1 and 8 of a 28 day cycle.  Pegylated Liposomal Doxorubicin is given Standard of Care schedule